Article in The Journal of cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Kilian TrilletCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.ORCID 0000-0003-0749-9871
Kathryn A JacobsCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.ORCID 0000-0003-3632-6400
Gwennan André-GrégoireCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.
An ThysCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.
Clément MagheCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.
Jonathan CruardCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.
Stéphane MinvielleCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.ORCID 0000-0003-1389-312X
Sara Gonzalez DiestCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.
Guillaume MontagnacInstitut National de la Santé et de la Recherche Médicale U1279, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.ORCID 0000-0001-6855-4446
Nicolas BidèreCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.ORCID 0000-0001-9177-0008
Julie GavardCentre de Recherche en Cancérologie et Immunologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Université d'Angers, Nantes, France.ORCID 0000-0002-7985-9007
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers · FRInserm · FR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Glioblastoma is one of the most lethal forms of adult cancer, with a median survival of ∼15 mo. Targeting glioblastoma stem-like cells (GSCs) at the origin of tumor formation and relapse may prove beneficial. In situ, GSCs are nested within the vascular bed in tight interaction with brain endothelial cells, which positively control their expansion. Because GSCs are notably addicted to apelin (APLN), sourced from the surrounding endothelial stroma, the APLN/APLNR nexus has emerged as a druggable network. However, how this signaling axis operates in gliomagenesis remains underestimated. Here, we find that the glycoprotein GP130 interacts with APLNR at the plasma membrane of GSCs and arbitrates its availability at the surface via ELMOD1, which may further impact on ARF-mediated endovesicular trafficking. From a functional standpoint, interfering with GP130 thwarts APLNR-mediated self-renewal of GSCs ex vivo. Thus, GP130 emerges as an unexpected cicerone to the G protein-coupled APLN receptor, opening new therapeutic perspectives toward the targeting of cancer stem cells.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The glycoprotein GP130 governs the surface presentation of the G protein-coupled receptor APLNR. · full record | OpenQuestion